Linzagolix choline is under clinical development by Kissei Pharmaceutical and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Linzagolix choline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Linzagolix choline overview
Linzagolix (Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist. It is formulated as film coated tablets for oral route of administration. Yselty is indicated for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age and for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Linzagolix choline is under development for the treatment of endometriosis associated pain and uterine fibroids. It is a new chemical entity (NCE). The drug candidate is administered orally as a film coated tablet. KLH-2109 targets gonadotrophin-releasing hormone (GnRH).
Kissei Pharmaceutical overview
Kissei Pharmaceutical (Kissei) is a pharmaceutical company. The company’s product portfolio includes medicines for urological, metabolic, endocrinological, obstetrics and gynecological, nephrological, ophthalmic, and pulmonary system disorders. The company sells protein-controlled foods, foods for the elderly and people receiving nursing care and energy supply foods. It also provides manufacturing and selling of noodle products, system integration and resource services, general construction and building management, information gathering and development support services. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto-Shi, Nagano, Japan.
For a complete picture of Linzagolix choline’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
